Achieved operating revenues of $4.54 billion, including core revenues of $4.10 billion Generated operating cash flow of $1.81 billion, excluding special items
Generated free cash flow of $677 million, excluding special items and integration-related capital expenditures Achieved Adjusted Net Income of $408 million and Adjusted Diluted EPS of $0.72, excluding special items Completed $2 billion 2013 share repurchase program; Repurchased 59.5 million shares since inception of program in February 2013, representing 9.6% of outstanding shares as of December 31, 2012 Commenced follow-on $1 billion share repurchase program in second quarter MONROE, La.
Net Sales of $479.4 million, up 17.9% from Q2 2013 Organic Revenue growth of over 2% during the quarter Adjusted EBITDA up 6.7% from Q2 2013
Completed Refinancing of 8.875% Notes and Term Loan Facility STAMFORD, Conn.
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of
automated, multiplex molecular diagnostic testing systems, will present
at the Canaccord Genuity 34th Annual Growth Conference to be held at the
InterContinental Boston Hotel in Boston, MA on Wednesday, August 13,
Tangoe, Inc. (NASDAQ: TNGO), a leading global provider of Connection
Lifecycle Management (CLM) software and related services, today
announced financial results for its second quarter ended June 30, 2014.
- 'Clinical Map Initiative' On Track; Human Proof of Concept Results for RG-101 and Nomination of Third Clinical Candidate Expected by YE 2014 - - Maintained Strong Financial Position Ending Q2 2014 with $103.5 Million in Cash -
LA JOLLA, Calif.
CARLSBAD, CA --
MarkWest Energy Partners, L.P. (NYSE: MWE) (“the Partnership”) today
reported quarterly cash available for distribution to common
unitholders, or distributable cash flow (DCF), of $161.7 million for the
three months ended June 30, 2014, and $310.2 million for the six months
ended June 30, 2014.
Rexnord Corporation (NYSE:RXN):
First Quarter Highlights
Net sales were $510 million
Income from operations was $58 million or 11% of net sales
Adjusted EBITDA was $93 million or 18% of net sales
Diluted earnings per share was $0.11, including a $10 million
non-cash, non-recurring tax restructuring charge
Excluding Mill Products (1) , net sales increased 2% year
over year (-1% core sales, +3% acquisitions). Mill Products'
contribution to earnings per share in the quarter was immaterial
Adjusted earnings per share, excluding Mill Products, increased 18%
from the prior year to $0.26
Total liquidity was $646 million ($311 million of cash plus $335
million of available borrowings)
Nortech Systems Incorporated (NASDAQ: NSYS) today reported net sales of
$27.4 million for the second quarter ended June 30, 2014, up five
percent sequentially from the prior quarter and compared with $28.5
million for the second quarter of 2013.
- Revenue of $118.1 million for the second quarter of 2014 - GAAP Net Income per Diluted Share of $0.30, and Non-GAAP Net Income per Diluted Share of $0.43
- Company adjusts full-year 2014 guidance for revenue to a range of $455 million to $470 million and for net income per diluted share to $0.80 to $0.90 on a GAAP basis and $1.25 to $1.35 on a non-GAAP basis - HeartMate III™ and HeartMate PHP™ begin CE Mark Trials; FDA grants conditional approval to start HeartMate III U.S. IDE trial PLEASANTON, Calif.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.